2,2-[(E)-3,3-Diphenyl­prop-2-ene-1,1-di­yl]bis­(3-hy­droxy­cyclo­hex-2-en-1-one)

In the title compound, C27H26O4, each of the cyclo­hexenone rings adopts a half-chair conformation. The dihedral angle between the two phenyl rings is 89.53 (5)°. The hy­droxy and carbonyl O atoms face each other and are orientated to allow the formation of two intra­molecular O—H⋯O hydrogen bonds, which are typical of xanthene derivatives

(E)-2,2′-[3-(2-Nitro­phen­yl)prop-2-ene-1,1-di­yl]bis­(3-hy­droxy­cyclo­hex-2-en-1-one)

In the title compound, C21H21NO6, each of the cyclo­hexenone rings adopts a half-chair conformation. Each of the pairs of hy­droxy and carbonyl O atoms are oriented to allow for the formation of intra­molecular O—H⋯O hydrogen bonds, which are typical of xanthene derivatives

(E)-2,2′-[3-(2-Nitro­phen­yl)prop-2-ene-1,1-di­yl]bis­(3-hy­droxy-5,5-dimethyl­cyclo­hex-2-en-1-one)

In the title compound, C25H29NO6, each of the cyclo­hexenone rings adopts a half-chair conformation. Each of the pairs of hy­droxy and carbonyl O atoms are oriented to allow for the formation of intra­molecular O—H⋯O hydrogen bonds, which are typical of xanthene derivatives. The nitro group is rotationally disordered over two orientations in a 0.544 (6):0.456 (6) ratio. In the crystal, weak inter­molecualr C—H⋯O hydrogen bonds link mol­ecules into layers parallel to the ab plane

(E)-9-(4-Chloro­styr­yl)-3,4,5,6,7,9-hexa­hydro-2H-xanthene-1,8-dione

In the title compound, C21H19ClO3, the two cyclo­hexenone rings adopt half-chair conformations, whereas the pyran ring adopts a boat conformation. The 4-chloro­phenyl ring is almost perpendicular to the plane through the four C atoms of the pyran ring [dihedral angle = 87.97 (6)°]. In the crystal, weak C—H⋯O hydrogen bonds link the mol­ecules into a chain parallel to the a-axis

[2-(4-Chloro­phen­yl)-5-phenyl­oxolan-3-yl](cyclo­penten­yl)methanone

In the title compound, C22H21ClO2, the oxolane ring adopts a twisted conformation. The dihedral angles between the mean plane of the oxolane ring and the mean planes of the 4-chloro­phenyl, phenyl and cyclo­pentenyl rings are 71.81 (18), 76.9 (18) and 82.08 (18)°, respectively

3-Hy­droxy-2-[(2E)-1-(2-hy­droxy-6-oxocyclo­hex-1-en-1-yl)-3-(2-meth­oxy­phen­yl)prop-2-en-1-yl]cyclo­hex-2-en-1-one

In the title compound, C22H24O5, each of the cyclo­hexenone rings adopts a half-chair conformation. The hy­droxy and carbonyl O atoms face each other and are orientated to allow for the formation of the two intra­molecular O—H⋯O hydrogen bonds which are typical of xanthene derivatives. In the crystal, weak inter­molecular C—H⋯O hydrogen bonds link mol­ecules into layers parallel to the ab plane

Percutaneous placement of self-expandable metallic stents in patients with obstructive jaundice secondary to metastatic gastric cancer after gastrectomy

OBJECTIVE: To evaluate the outcomes of patients undergoing percutaneous placements of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy. MATERIALS AND METHODS: Fifty patients (mean age, 62.4 years; range, 27-86 years) who underwent percutaneous placements of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy were included. The technical success rate, clinical success rate, complication rate, stent patency, patient survival and factors associated with stent patency were being evaluated. RESULTS: The median interval between the gastrectomy and stent placement was 23.1 months (range, 3.9-94.6 months). The 50 patients received a total of 65 stents without any major procedure-related complications. Technical success was achieved in all patients. The mean total serum bilirubin level, which had been 7.19 mg/dL ± 6.8 before stent insertion, decreased to 4.58 mg/dL ± 5.4 during the first week of follow-up (p < 0.001). Clinical success was achieved in 42 patients (84%). Percutaneous transhepatic biliary drainage catheters were removed from 45 patients (90%). Infectious complications were noted in two patients (4%), and stent malfunction occurred in seven patients (14%). The median stent patency was 233 ± 99 days, and the median patient survival was 179 ± 83 days. Total serum bilirubin level after stenting was an independent factor for stent patency (p = 0.009). CONCLUSION: Percutaneous transhepatic placement of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy is a technically feasible and clinically effective palliative procedure

Evaluation of the TEST 1 erythrocyte sedimentation rate system and intra- and inter-laboratory quality control using new latex control materials

Background: The erythrocyte sedimentation rate (ESR) test has been considered to be a simple procedure, not requiring quality control (QC). However, QC is essential for accuracy and precision. We evaluated the TEST 1 ESR system and performed QC procedures using newly developed latex control materials in three hospitals. Methods: Using tripotassium ethylenediaminetetraacetic acid blood samples (n=184), we compared TEST 1 ESR values with Westergren ESR data and evaluated intra-assay precision. Three levels of latex control materials were used to assess inter-assay precision. Reference range assessment was done using samples from 220 healthy individuals. Inter-laboratory QC with latex control materials in three hospitals was performed. Results: Correlation between TEST 1 ESR and Westergren ESR results was good (p<0.001). Intra-assay precision [coefficients of variation (CV) 6.6%-21.7%] with patient samples and inter-assay precision (CV 0.0%-6.8%) with latex control materials were satisfactory. The reference ranges of 2-10 mm/h for males and 2-19 mm/h for females were established. Inter-laboratory QC data with latex control materials in three hospitals demonstrated good accuracy and satisfactory precision (CV 0.0%-14.4%). Conclusions: Our results demonstrate that the TEST 1 QC is reliable and the latex control materials are valuable for inter-laboratory proficiency testing. Clin Chem Lab Med 2010; 48: 1043-8.Cha CH, 2009, AM J CLIN PATHOL, V131, P189, DOI 10.1309/AJCPOU1ASTLRANIJ*CLIN LAB STAND I, 2008, C28A3 CLSIPiva E, 2007, CLIN BIOCHEM, V40, P491, DOI 10.1016/j.clinbiochem.2006.12.002Padro-Miquel A, 2007, CLIN CHEM LAB MED, V45, P930, DOI 10.1515/CCLM.2007.150Romero A, 2003, CLIN CHEM LAB MED, V41, P232Plebani M, 2002, AM J CLIN PATHOL, V117, P621LEE BH, 2002, J CLIN PATHOL QUALIT, V24, P167GIAVARINA D, 2002, CLIN LAB, V48, P459Piva E, 2001, CLIN CHEM LAB MED, V39, P451*CLIN LAB STAND I, 2000, H2A4 CLSIPlebani M, 1998, AM J CLIN PATHOL, V110, P334BULL BS, 1993, J CLIN PATHOL, V46, P198BULL BS, 1991, PRACTICAL LAB HEMATOFABRY TL, 1987, BLOOD, V70, P1572WESTERGREN A, 1926, AM REV TUBERC, V14, P94